New substituted pyrazole derivatives targeting COXs as potential safe anti-inflammatory agents.

Everyday studies prove the increasing need for newer and safer agents to control cellular inflammatory response, an underlying cause for the pathophysiology of many other clinical cases. Two newly designed sets of schiff and chlacone substituted pyrazoles were synthesized and evaluated for their anti-inflammatory activities. Most potent representatives were chosen for investigation of ulcerogenic and molecular docking properties The synthesized compounds showed considerable edema inhibition percentage range if compared with celecoxib (13-93% and 58-93%, respectively) at different time intervals. Compound showed the best screening results if compared with celecoxib (inhibition % = 93.62 and 93.51% at 5 h, COX-1/COX-2 selectivity index SI = 215.44 and 308.16 and ulcer index = 7.25 and 8, respectively).